Diagnostic performances of interleukin-12
P70, 17 and 18 in diagnosing diabetes mellitus type 2 with diabetic foot ulcer group and in separating it from control group Biomarkers Cut-off values AUC SE of AUC 95% CI of AUC p values IL-12 P70 >5.42 0.736 0.0653 0.608 to 0.840 <0.001 IL-17 >3.3 0.791 0.0576 0.669 to 0.884 <0.001 IL-18 >407.2 0.723 0.0652 0.594 to 0.829 <0.001 Predictive values (%) Biomarkers Sens.
Stanzlet al., "Interleukin-12
is produced by dendritic cells and mediates T helper 1 development as well as interferon-y production by T helper 1 cells," European Journal of Immunology, vol.
Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12
in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
Kapsenberg, "Prostaglandin E(2) is a selective inducer of interleukin-12
p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer," Blood, vol.
APCs: Antigen-presenting cells BMI: Body mass index CRP: C-reactive protein CFU: Colony-forming unit DBP: Diastolic blood pressure DV: Dependent variable HbA1c: Glycated hemoglobin IL10: Interleukin-10 IL12: Interleukin-12
IL6: Interleukin-6 IFN[gamma]: Interferon-gamma TNF [alpha]: Tumor necrosis factor-alpha T1DM: Diabetes mellitus type 1 T2DM: Diabetes mellitus type 2 TLR 2: Toll-like receptor 2 SBP: Systolic blood pressure.
and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis.
Its immunotherapy platform, ImmunoPulse, a naturally occurring protein with immune-stimulating functions focuses on the delivery of DNA-based interleukin-12
in anti-tumor immunity and immunotherapy.
She described imiquimod as an immune response modifier that induces mRNA encoding cytokines like alphainterferon, TNF, and interleukin-12
for a cytotoxic T-lymphocyte response.
In an immunocompetent host, once adequate cell-mediated immunity develops, the infection is eliminated by cytokines including interleukin-12
and interferon gamma that help "armed" macrophages in either killing the organism or halt its progression by forming a calcified granuloma .
Andreadou et al., "Circulating interleukin-10 and interleukin-12
in Parkinson's disease," Acta Neurologica Scandinavica, vol.